Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference33 articles.
1. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248–1253.
2. Casey R, Love W, Mendoza C, Reymond D, Zarenda M . Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen deprivation therapy. The 2006 Multidisciplinary Prostate Cancer Symposium, 24–26 February 2006; San Francisco, Calif. Abstract 184.
3. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038–1042.
4. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–2012.
5. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Shoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948–955.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献